Haobo Ren

2.2k total citations · 1 hit paper
51 papers, 1.6k citations indexed

About

Haobo Ren is a scholar working on Dermatology, Immunology and Allergy and Immunology. According to data from OpenAlex, Haobo Ren has authored 51 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Dermatology, 10 papers in Immunology and Allergy and 9 papers in Immunology. Recurrent topics in Haobo Ren's work include Dermatology and Skin Diseases (13 papers), Allergic Rhinitis and Sensitization (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers). Haobo Ren is often cited by papers focused on Dermatology and Skin Diseases (13 papers), Allergic Rhinitis and Sensitization (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers). Haobo Ren collaborates with scholars based in United States, Canada and France. Haobo Ren's co-authors include Jennifer D. Hamilton, Allen Radin, Neil M.H. Graham, Gianluca Pirozzi, Diamant Thaçi, Thomas Bieber, Steven P. Weinstein, Marius Ardeleanu, Eric L. Simpson and Ross E. Rocklin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Haobo Ren

45 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

2014 1.0k citations Lisa A. Beck, Diamant Thaçi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haobo Ren United States	15	891	684	489	296	275	51	1.6k
Yuting Zhang China	10	311 0.3×	215 0.3×	60 0.1×	9 0.0×	454 1.7×	36	2.3k
Evangelia Zampeli Greece	19	40 0.0×	96 0.1×	206 0.4×	393 1.3×	484 1.8×	59	1.2k
Richard W. Erickson United States	17	25 0.0×	175 0.3×	720 1.5×	72 0.2×	844 3.1×	20	1.6k
Masahiro Iwasaki Japan	20	58 0.1×	97 0.1×	265 0.5×	46 0.2×	252 0.9×	55	1.7k
András Berta Hungary	31	60 0.1×	74 0.1×	106 0.2×	86 0.3×	120 0.4×	133	3.2k
Juan Ding United States	19	134 0.2×	100 0.1×	154 0.3×	18 0.1×	39 0.1×	56	1.1k
J.R. Marsden United Kingdom	20	227 0.3×	28 0.0×	27 0.1×	54 0.2×	382 1.4×	44	1.2k
Michelle Goh Australia	16	210 0.2×	33 0.0×	39 0.1×	113 0.4×	187 0.7×	43	1.1k
Juan Ding China	14	96 0.1×	93 0.1×	79 0.2×	40 0.1×	56 0.2×	48	1.2k
Murat Borlu Türkiye	17	186 0.2×	14 0.0×	46 0.1×	163 0.6×	63 0.2×	70	818

Countries citing papers authored by Haobo Ren

Since Specialization

Citations

This map shows the geographic impact of Haobo Ren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haobo Ren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haobo Ren more than expected).

Fields of papers citing papers by Haobo Ren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haobo Ren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haobo Ren. The network helps show where Haobo Ren may publish in the future.

Co-authorship network of co-authors of Haobo Ren

This figure shows the co-authorship network connecting the top 25 collaborators of Haobo Ren. A scholar is included among the top collaborators of Haobo Ren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haobo Ren. Haobo Ren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosmarin, David, Amit G. Pandya, Thierry Passeron, et al.. (2025). Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatology and Therapy. 15(12). 3703–3716.

Ren, Haobo, Lihua Zhan, & Youliang Yang. (2025). Creep Aging Fracture Behavior of 7050 Aluminum Alloy with Different Process Parameters : Experiment and Constitutive Model. Journal of Physics Conference Series. 3104(1). 12007–12007.

Eichenfield, Lawrence F., Eric L. Simpson, Kim Papp, et al.. (2024). Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. American Journal of Clinical Dermatology. 25(4). 669–683. 8 indexed citations

Saverno, Kim, Kristin M. Zimmerman Savill, Michael Rodriguez, et al.. (2024). Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US. The Oncologist. 30(1).

Harris, John E., David Rosmarin, Julien Sénéschal, et al.. (2023). 43912 Facial Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies. Journal of the American Academy of Dermatology. 89(3). AB48–AB48. 1 indexed citations

Simpson, Eric L., Leon Kircik, Andrew Blauvelt, et al.. (2023). Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy. The Journal of Dermatology. 50(12). 1523–1530. 2 indexed citations

Rosmarin, David, John E. Harris, Albert Wolkerstorfer, et al.. (2023). 43938 Total Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies. Journal of the American Academy of Dermatology. 89(3). AB240–AB240. 1 indexed citations

Hamzavi, Iltefat, Kristen Bibeau, Pearl E. Grimes, et al.. (2023). Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. British Journal of Dermatology. 189(5). 569–577. 16 indexed citations

Ezzedine, Khaled, Thierry Passeron, David Rosmarin, et al.. (2023). 43959 Vitiligo Noticeability Scale Score Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies. Journal of the American Academy of Dermatology. 89(3). AB104–AB104. 1 indexed citations

10.

Bibeau, Kristen, Khaled Ezzedine, John E. Harris, et al.. (2023). Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo. JAMA Dermatology. 159(10). 1124–1124. 49 indexed citations

11.

Bibeau, Kristen, Luis Féliz, Christine Lihou, Haobo Ren, & Ghassan K. Abou‐Alfa. (2022). Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO Precision Oncology. 6(6). e2100414–e2100414. 20 indexed citations

12.

Abou‐Alfa, Ghassan K., Kristen Bibeau, Nikolaus Schultz, et al.. (2022). Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targeted Oncology. 17(5). 517–527. 22 indexed citations

13.

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2022). Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology. 88(5). 1008–1016. 58 indexed citations

14.

Gordon, Kenneth B., Kim Papp, Melinda Gooderham, et al.. (2020). 15026 BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis. Journal of the American Academy of Dermatology. 83(6). AB140–AB140. 2 indexed citations

15.

Chiu, Chi‐Yang, Jeesun Jung, Wei Chen, et al.. (2016). Meta-analysis of quantitative pleiotropic traits for next-generation sequencing with multivariate functional linear models. European Journal of Human Genetics. 25(3). 350–359. 4 indexed citations

16.

Fan, Ruzong, Yifan Wang, Michael Boehnke, et al.. (2015). Gene Level Meta-Analysis of Quantitative Traits by Functional Linear Models. Genetics. 200(4). 1089–1104. 23 indexed citations

17.

Beck, Lisa A., Diamant Thaçi, Jennifer D. Hamilton, et al.. (2014). Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine. 371(2). 130–139. 1008 indexed citations breakdown →

18.

Tiseo, Paul J., Alan Kivitz, John Ervin, Haobo Ren, & Scott Mellis. (2014). Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 155(7). 1245–1252. 88 indexed citations

19.

Williams, Linda, Paul J. Tiseo, Haobo Ren, & Scott Mellis. (2014). Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. Journal of Pain Research. 7. 523–523. 14 indexed citations

20.

Quan, Hui, et al.. (2010). Benefit-Risk Assessments in Dose-Finding Trials. Statistics in Biopharmaceutical Research. 2(2). 153–164. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact